GlassScriptPhysician profile
Vijay Gopal Hegde
NPI 1821021122
$7,090.37
in general payments reported to CMS, 2019-2025
39 companies · $2,916 in 2025
The $2,916 reported for 2025 was more than what 92% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $238 · 2022: $125 · 2023: $1,096 · 2024: $2,716 · 2025: $2,916.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,727.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,726.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,212.31 | 2022-2025 | |
| Pfizer INC. | $532.54 | 2023-2025 | |
| Eisai INC. | $505.04 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $450.42 | 2023-2025 | Ingrezza, Ongentys |
| Lundbeck LLC | $399.68 | 2023-2025 | Vyepti, Rexulti |
| Lilly USA, LLC | $378.90 | 2023-2025 | Kisunla, Amyvid, Emgality |
| Teva Pharmaceuticals USA, INC. | $368.05 | 2023-2025 | Austedo Xr, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $343.46 | 2023-2025 | Nuedexta, Rexulti |
| Celgene Corporation | $295.25 | 2024-2025 | Zeposia |
| Alexion Pharmaceuticals, INC. | $238.42 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $235.49 | 2024 | Zeposia |
| Amneal Pharmaceuticals LLC | $234.73 | 2023-2025 | Rytary, Crexont, Ongentys 50mg Capsules 30 |
| Vanda Pharmaceuticals INC. | $234.67 | 2025 | Ponvory |
| Novartis Pharmaceuticals Corporation | $224.79 | 2024-2025 | |
| Merz Pharmaceuticals, LLC | $179.45 | 2024-2025 | Xeomin, Inbrija |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $170.62 | 2024-2025 | Nuplazid |
| Argenx US, INC. | $161.15 | 2025 | Vyvgart Hytrulo |
| Ge Healthcare | $97.53 | 2023-2024 | |
| Mallinckrodt Hospital Products INC. | $92.15 | 2025 | Acthar |
| Cycle Pharmaceuticals INC | $90.10 | 2024-2025 | Tascenso Odt, Bafiertam |
| Acorda Therapeutics, INC | $81.52 | 2023-2024 | Inbrija, Ampyra |
| Genentech USA, INC. | $65.91 | 2025 | Ocrevus Zunovo |
| Janssen Biotech, INC. | $55.82 | 2025 | |
| Microtransponder, INC. | $40.32 | 2024-2025 | |
| Mdd US Operations, LLC | $39.62 | 2024-2025 | Gocovri |
| Inspire Medical Systems, INC. | $37.99 | 2024 | Inspire |
| Kyowa Kirin, INC. | $34.03 | 2023-2024 | Nourianz |
| C2n Diagnostics, LLC | $30.96 | 2025 | Precivityad2 |
| Amgen INC. | $30.24 | 2024 | Uplizna |
| Corium, LLC | $28.56 | 2023 | Adlarity |
| Axsome Therapeutics, INC. | $28.51 | 2025 | Symbravo |
| Nevro Corp. | $28.24 | 2023 | Senza |
| Boston Scientific Corporation | $27.06 | 2025 | Vercise |
| Ani Pharmaceuticals, INC. | $24.68 | 2025 | Purified Cortrophin Gel |
| Averitas Pharma INC. | $19.63 | 2025 | Qutenza |
| Astrazeneca Pharmaceuticals LP | $19.43 | 2023 | Andexxa |
| Revance Therapeutics, INC. | $18.28 | 2025 | Daxxify |
| Insightec,INC | $17.62 | 2025 | Exablate |
| Janssen Pharmaceuticals, INC | $17.20 | 2024 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vijay Hegde listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.